{
    "id": 23596,
    "fullName": "MAP2K2 V35M",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "MAP2K2 V35M does not lie within any known functional domains of the Map2k2 protein (UniProt.org). V35M has been associated with resistance to RAF and MEK inhibitors (PMID: 24265153, PMID: 28263969), but has not been biochemically characterized and therefore, its effect on Map2k2 protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 8508,
                    "pubMedId": 28263969,
                    "title": "Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28263969"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5605,
        "geneSymbol": "MAP2K2",
        "terms": [
            "MAP2K2",
            "CFC4",
            "MAPKK2",
            "MEK2",
            "MKK2",
            "PRKMK2"
        ]
    },
    "variant": "V35M",
    "createDate": "06/23/2016",
    "updateDate": "10/13/2019",
    "referenceTranscriptCoordinates": {
        "id": 158855,
        "transcript": "NM_030662",
        "gDna": "chr19:g.4117619C>T",
        "cDna": "c.103G>A",
        "protein": "p.V35M",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7053,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 V35M demonstrated resistance to treatment with Mekinist (trametinib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24313,
                "profileName": "BRAF V600E MAP2K2 V35M"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7009,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 V35M demonstrated sensitivity to treatment with VRT11E, resulting in decreased cell growth in culture (PMID: 24265153).",
            "molecularProfile": {
                "id": 24313,
                "profileName": "BRAF V600E MAP2K2 V35M"
            },
            "therapy": {
                "id": 4351,
                "therapyName": "VRT11E",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7050,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, melanoma cells harboring BRAF V600E and expressing MAP2K2 V35M demonstrated resistance to treatment with Tafinlar (dabrafenib) in culture, resulting in sustained Map2k1/2 and Erk1/2 phosphorylation (PMID: 24265153).",
            "molecularProfile": {
                "id": 24313,
                "profileName": "BRAF V600E MAP2K2 V35M"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5840,
                    "pubMedId": 24265153,
                    "title": "The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24265153"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 24299,
            "profileName": "MAP2K2 V35M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24313,
            "profileName": "BRAF V600E MAP2K2 V35M",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 158857,
            "transcript": "XM_017026989",
            "gDna": "chr19:g.4117619C>T",
            "cDna": "c.103G>A",
            "protein": "p.V35M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 158856,
            "transcript": "XM_017026990",
            "gDna": "chr19:g.4117619C>T",
            "cDna": "c.103G>A",
            "protein": "p.V35M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 158855,
            "transcript": "NM_030662",
            "gDna": "chr19:g.4117619C>T",
            "cDna": "c.103G>A",
            "protein": "p.V35M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 158854,
            "transcript": "XM_006722799",
            "gDna": "chr19:g.4117619C>T",
            "cDna": "c.103G>A",
            "protein": "p.V35M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 158858,
            "transcript": "XM_017026991",
            "gDna": "chr19:g.4117619C>T",
            "cDna": "c.103G>A",
            "protein": "p.V35M",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}